Phase 1 Bladder Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You have been diagnosed with a type of bladder cancer called urothelial carcinoma (either pure or mixed with certain other subtypes).
- You have had your bladder surgically removed (radical cystectomy) along with nearby lymph nodes within the past 48 weeks.
- Your cancer was found to be at an advanced stage (T3 or higher) at the time of surgery, with no spread to distant parts of the body.
- You are currently receiving a type of cancer treatment called a checkpoint inhibitor (an immunotherapy drug given after surgery).
- There is no sign of remaining or returning cancer based on recent physical exam and imaging scans done within the last 3 months.
- You are considered a suitable candidate for external beam radiation therapy (a type of radiotherapy given from outside the body), as confirmed by a radiation specialist.
- You have not had radiotherapy to the area being treated in this trial before.
- You are 18 years of age or older.
- You are generally able to carry out daily activities (your physical functioning falls within an acceptable range on a standard medical scale).
- A planning scan done before the trial also shows no signs of cancer returning.
- You are able to understand and sign a consent form agreeing to take part in the study.
Who may not be able to join:
- You had a specific type of bladder reconstruction surgery called an orthotopic neobladder (where a new bladder is made from part of your bowel).
- You have a history of inflammatory bowel disease (such as Crohn's disease or ulcerative colitis).
- You have previously had a blockage in your small bowel (small bowel obstruction), either before or after your bladder removal surgery.
- You have had radiotherapy to the pelvis before, unless it was for a completely different condition, finished more than four weeks ago, and the radiation fields would not overlap with this treatment (confirm with trial site).
- You are planning to receive chemotherapy or another experimental drug at the same time as the radiation treatment in this trial.
- After surgery, there is still clearly visible cancer remaining that can be seen on scans or felt during a physical exam.
- You have had or currently have another serious cancer that, in the opinion of the study doctors, could affect the trial results.
- You have a significant other illness or health condition that the study doctors believe could make it unsafe or difficult for you to complete the trial.
- You experienced severe (Grade 3 or higher) digestive side effects (such as serious bowel problems) caused by your surgery or by the immunotherapy drug nivolumab before joining the trial.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: John Christodouleas, MD, University of Pennsylvania
Phone: 215-662-3790
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Safety of concurrent adjuvant immunotherapy and radiation therapy
Can't join this trial?
Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.